IMM: Discontinuation of TACTI-004 caused impairment, but strong cash and positive clinical data support future prospects
IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity
02:19 ETImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
02:40 ETIMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
03:02 ETImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP